Matrixyl 3000

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Both components of Matrixyl 3000 — palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 — are regulated as cosmetic ingredients in the United States under FDA cosmetics law, including the Modernization of Cosmetics Regulation Act (MoCRA, 2022). Neither ingredient is an FDA-approved drug, and neither appears on the FDA bulk drug substance restricted lists that govern compounded pharmaceuticals. No prescription is required for purchase or use in finished cosmetic products. MoCRA facility and product registration obligations apply to finished-product marketers (phased deadlines from July 2024). The CIR Expert Panel has affirmed safety as used.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Matrixyl 3000

Origin

Developed and commercialised by Sederma (now part of Croda Inc.) under the trade name Matrixyl® 3000. The blend combines two palmitoylated synthetic peptides: palmitoyl tripeptide-1 (Pal-GHK; INCI: Palmitoyl Tripeptide-1), whose GHK core is derived from the C-terminal domain of the alpha-2 chain of collagen I, and palmitoyl tetrapeptide-7 (Pal-GQPR; also known as Rigin®), whose GQPR core was identified by Sederma researchers as a biologically active fragment of the Fc region of immunoglobulin G. The blend is a proprietary mixture rather than a single chemical entity; no single PubChem CID or InChI key is applicable to the combination as a whole.

Appearance

The Matrixyl 3000 complex is typically supplied as a clear to slightly yellow aqueous-glycol solution by ingredient vendors; individual peptide powders are white to off-white (vendor-typical). No single chemical appearance applies to the blend.

Solubility

Both peptides carry lipophilic palmitoyl chains that reduce free aqueous solubil…

Sequence not available in current seed.

Stability: Hydrolysis of palmitoyl ester bonds is the primary degradation pathway in aqueous media, accelerated by heat and pH extremes. The blend is marketed as stable at

Vial sizes

null mg

Purity grades

cosmetic grade

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Palmitoyl tripeptide-1 functions as a matrikine: the GHK sequence mimics collagen type I degradation fragments generated in vivo by matrix metalloproteinases, engaging fibroblast surface receptors (including integrin and TGF-β pathways) to stimulate synthesis of collagen types I, III, and IV, fibronectin, and hyaluronic acid
• The conjugated palmitoyl chain facilitates partitioning through the stratum corneum lipid bilayers, improving delivery to the dermis relative to free peptides
• Palmitoyl tetrapeptide-7 (Pal-GQPR) complements this by suppressing interleukin-6 (IL-6) release from keratinocytes; IL-6 upregulates matrix metalloproteinases and drives chronic low-grade dermal inflammation ('inflammaging') that accelerates collagen turnover
• The combination was formulated on the rationale that durable ECM rebuilding requires both stimulation of fibroblast matrix synthesis and attenuation of the inflammatory microenvironment that degrades newly synthesised matrix

Pharmacokinetics (ADME)

PK–PD note: No formal systemic pharmacokinetic parameters (Cmax, AUC, t½, clearance) have been published for either component of Matrixyl 3000. Both peptides are topically applied cosmetic ingredients; systemic a…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Nukaly et al. 2026 — Oral and topical peptides for skin aging: systematic review and meta-analysis of RCTs (Front Med; 19 RCTs, n=1,341; CRD420250652779) — Peptide-class anchor SR; modest pooled wrinkle effect (MD=0.27, p=0.04) driven mainly by oral polypeptides; not Matrixyl-3000-specific.
• Gorouhi & Maibach 2009 — Role of topical peptides in preventing or treating aged skin (Int J Cosmet Sci 31:327-345) — Foundational narrative review establishing the four-class peptide framework (signal/carrier/neurotransmitter-inhibitor/enzyme-inhibitor); classified Matrixyl among the more evidence-supported peptide ingredients at the time.
• Cosmetic Ingredient Review (CIR) — Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics (2012/2018) — CIR Expert Panel safety review covering palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 (Matrixyl 3000 components); tentative 'safe as used' conclusion for cosmetic use concentrations.
• Kachooeian et al. 2022 — Matrixyl Patch vs Matrixyl Cream: Comparative In Vivo Investigation of MTI Effect on Wound Healing (ACS Omega 7(28):24695-24704; PMID 35874243) — Animal (in vivo) study; wound-healing endpoint, not cosmetic anti-aging; MTI = Matrixyl. Demonstrates mechanistic/animal evidence layer only.

No registered human trials found for this compound.

Status

No registered trials found

Summary (literature)

The Cosmetic Ingredient Review (CIR) Expert Panel conducted a formal safety assessment of tripeptide-1, its metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 (Johnson et al., Int J Toxicol, 2018; doi: 10.1177/1091581818807863), concluding that these ingredients…

WADA status

Not specifically listed on the 2026 WADA Prohibited List. Palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 are topically applied cosmetic ingredients with no…

Dominant research route: Topical (cream/serum/patch)

Human in-vivo skin-penetration tracking (3D OrbiSIMS, n=12) and Sederma clinical panels (e.g., 8-week, 30-participant cream with 5% palmitoyl oligopeptides); also studied in vitro on human dermal fibroblasts

Bioavailability: Palmitoylation of the GHK/GQPR peptide sequences improves cutaneous penetration ~100–1000× over the unmodified hydrophilic peptide; 3D OrbiSIMS detected the Matrixyl 3000+ peptide blend penetrating into the stratum corneum (the rate-limiting barrier) in vivo. No formal pharmacokinetic parameters (Cmax, AUC, half-life) have been determined and systemic absorption from topical application has not been detected.

Dominant research route. Studied as a cosmetic active in creams/serums; passive diffusion through the stratum corneum is the limiting step. This describes what was studied, not a human protocol.

Animal (rat) in-vivo wound-healing model, 21-day study comparing MTI-loaded patch vs MTI cream vs controls

Bioavailability: Patch delivery bypasses the stratum corneum and produced greater re-epithelialization and wound-closure (up to 81.81% vs negative control) than the equivalent MTI cream in the rat model; both outperformed positive control (Comfeel).

Patch vs cream comparative study (Kachooeian et al., ACS Omega 2022) demonstrates delivery-mode dependence of Matrixyl (MTI) biological effects; animal data only, not a human protocol.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Researched storefront prices, bucketed

p25 $0.900 · median $1.39 · p75 $2.29 · 7 researched vendors

Legit, COA-backed band: $0.850–$1.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$9

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

HPLC purity of the peptide fraction is commonly reported as ≥98–99.66% (e.g., MedChemExpress 99.66% for palmitoyl pentapeptide-4; Dermafactors ≥99% for palmitoyl tetrapeptide-7; an academic HPLC assay estimated ~97% purity). However, commercial Matrixyl 3000 is supplied as a liquid concentrate whose net peptide content (PT-1 + PT-7 per gram of supplied material) is typically only 0.1–2.0% — so a '≥98% purity' COA refers to the peptide fraction, not to peptide-per-gram of the product.

Independent labs cited for this compound

No FDA recalls, market withdrawals, enforcement reports, or import alerts naming Matrixyl 3000 (palmitoyl tripeptide-1 / palmitoyl tetrapeptide-7) were found in FDA's recall, enforcement-report, or import-alert databases. Matrixyl 3000 is regulated as a cosmetic ingredient rather than a drug, so the recall/enforcement apparatus applicable to injectable research peptides does not generally attach to it. None found.

Buyer red-flag checklist

• Generic Matrixyl 3000 equivalents are sold as liquid concentrates with net peptide content of only ~0.1–2.0% of supplied weight; a COA stating 'HPLC ≥98% purity' refers to the peptide fraction, not to peptide-per-gram, leading to massive under-delivery of active peptide in finished formulas.
• Suppliers frequently omit the net peptide content per gram as a separate COA field; if a supplier cannot state the absolute mg/g of PT-1 + PT-7, the actual peptide delivery cannot be calculated or price-compared meaningfully.
• Palmitoyl ester bonds in PT-1 and PT-7 hydrolyse above ~45°C, silently destroying the amphiphilic structure required for skin penetration; suppliers who do not specify a cool-down addition step provide inadequate documentation.
• Formaldehyde-releasing preservatives (DMDM Hydantoin, Imidazolidinyl Urea, Diazolidinyl Urea) covalently modify and inactivate the peptide over shelf life via Schiff-base formation with free amine groups, with no visible change in appearance or odor.
• The 'Matrixyl 3000' name is a Sederma trademark; generic equivalents may use the same two-peptide combination but with unverified PT-1:PT-7 ratio and inconsistent batch-to-batch proportions.
• Amazon-listed 'Matrixyl 3000' serums/ampoules (e.g., THEPURI) market 'Sederma France' branding without independent verification of Sederma sourcing or peptide content.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent third-party lab tests (Janoshik, MZ Biolabs, Finnrick) specifically naming Matrixyl 3000 / palmitoyl tripeptide-1 / palmitoyl tetrapeptide-7 were located in public databases. The gray-market peptide underdosing documented by Janoshik pertains to injectable research peptides (BPC-157, TB-500, semaglutide, etc.), not to cosmetic matrikine concentrates. The closest quality concern is not classical underdosing but net-peptide-content misrepresentation: generic suppliers cite HPLC purity of the peptide fraction while the supplied concentrate contains only ~0.1–2.0% actual peptide, so a formulator adding '2% Matrixyl 3000' may be delivering ~0.01% active peptide.

• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Not prohibited. Matrixyl 3000 (palmitoyl tripeptide-1 / palmitoyl tetrapeptide-7) is a cosmetic ingredient, not a pharmacological agent under WADA's framework; it does not appear on the WADA Prohibited List.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Sponsored YouTube content (e.g., Depology sponsorship)
• Affiliate-linked blog reviews
• Self-reported anecdotal outcomes without controls
• Brand-affiliated marketing language in retailer listings
• Small self-selecting commenter sample

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Sederma's two-peptide cosmetic blend (Pal-GHK + Pal-GQPR) combining a matrikine collagen-signalling peptide with an anti-inflammatory IgG-derived tetrapeptide. Approximately 0 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Cosmetic ingredient (OTC, no prescription required). Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet